SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
Specialty clinical-stage pharmaceutical company SciSparc Ltd. (NASDAQ:SPRC) has entered into a merger agreement with AutoMax Motors Ltd., a vehicle importer company in Israel. Deal terms not disclosed.
处于临床阶段的专业制药公司ScisPARC Ltd.（纳斯达克股票代码：SPRC）已与以色列的汽车进口公司AutoMax Motors Ltd. 签订了合并协议。交易条款未披露。
The strategic move entails SciSparc securing full ownership of AutoMax and establishing a fresh subsidiary in Israel that will subsequently merge with AutoMax.
该战略举措需要ScisPARC获得AutoMax的全部所有权，并在以色列建立新的子公司，该子公司随后将与AutoMax合并。
This merger aims to form a new entity with SciSparc shareholders owning slightly more than 50% of its capital, aligning with the company's strategy to seek value-enhancing opportunities. SciSparc's ongoing pharmaceutical operations will continue seamlessly after the merger.
此次合并旨在组建一个新实体，ScisPARC的股东拥有略高于其50％的资本，这与公司寻求价值提升机会的战略一致。合并后，ScisPARC正在进行的制药业务将无缝继续。
Post-merger, AutoMax shares will convert to SciSparc ordinary share rights, with its stakeholders owning approximately 49.99% of the merged entity, subject to adjustments. SciSparc commits to a minimum of $4.25 million in net cash at deal closure.
合并后，AutoMax的股票将转换为ScisPARC普通股权，其利益相关者拥有合并后实体约49.99％的股份，但须进行调整。ScisPARC承诺在交易完成时提供至少425万美元的净现金。
Notably, both companies share a chairman Amitai Weiss, indicating a close relationship at the leadership level, underscoring the merger's role in SciSparc's diversification into the automotive industry.
值得注意的是，两家公司共用一名董事长阿米泰·魏斯，这表明在领导层关系密切，这凸显了合并在ScisPARC向汽车行业多元化发展中的作用。
Price Action: SPRC shares are trading higher by 6.88% at $1.79 on Thursday.
价格走势：周四，SPRC股价上涨6.88％，至1.79美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明： 该内容部分是在人工智能工具的帮助下制作的，并由Benzinga编辑审阅和发布。
Image sourced from Shutterstock
图片来自 Shutterstock
译文内容由第三方软件翻译。